Extended Data Fig. 6: Different immune signatures in long-term versus short-term survivors from the PPP2R1A-mutant group.
From: PPP2R1A mutations portend improved survival after cancer immunotherapy
a. Pathway analysis based on the transcriptomic-level comparison of samples from long-term versus short-term survivors in the pretreatment timepoint. b-c. Enriched pathways (b) and representative DEGs (c) based on the transcriptomic-level comparison of samples from long-term versus short-term survivors in the on-treatment timepoint.
